251 related articles for article (PubMed ID: 22326755)
21. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
[TBL] [Abstract][Full Text] [Related]
22. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
[TBL] [Abstract][Full Text] [Related]
23. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.
Chen Y; Sun Y; Rao Q; Xu H; Li L; Chang C
Oncotarget; 2015 Oct; 6(31):31203-15. PubMed ID: 26304926
[TBL] [Abstract][Full Text] [Related]
25. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.
Liu W; Chen H; Wong N; Haynes W; Baker CM; Wang X
Cancer Lett; 2017 May; 394():65-75. PubMed ID: 28257806
[TBL] [Abstract][Full Text] [Related]
26. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
28. Loss of Von Hippel-Lindau (
Kim H; Shim BY; Lee SJ; Lee JY; Lee HJ; Kim IH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575959
[TBL] [Abstract][Full Text] [Related]
29. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma.
Chow TF; Mankaruos M; Scorilas A; Youssef Y; Girgis A; Mossad S; Metias S; Rofael Y; Honey RJ; Stewart R; Pace KT; Yousef GM
J Urol; 2010 Feb; 183(2):743-51. PubMed ID: 20022054
[TBL] [Abstract][Full Text] [Related]
30. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
31. Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner.
Huang Q; Sun Y; Zhai W; Ma X; Shen D; Du S; You B; Niu Y; Huang CP; Zhang X; Chang C
Oncogene; 2020 Oct; 39(43):6677-6691. PubMed ID: 32943729
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk.
Wei H; Ke HL; Lin J; Shete S; Wood CG; Hildebrandt MA
Mol Carcinog; 2014 Jan; 53(1):1-7. PubMed ID: 22517515
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
34. Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas.
Bouhamdani N; Joy A; Barnett D; Cormier K; Léger D; Chute IC; Lamarre S; Ouellette R; Turcotte S
Int J Cancer; 2017 Aug; 141(4):778-790. PubMed ID: 28486780
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
[TBL] [Abstract][Full Text] [Related]
36. Senescence-associated protein p400 is a prognostic marker in renal cell carcinoma.
Macher-Goeppinger S; Bermejo JL; Schirmacher P; Pahernik S; Hohenfellner M; Roth W
Oncol Rep; 2013 Nov; 30(5):2245-53. PubMed ID: 23982490
[TBL] [Abstract][Full Text] [Related]
37. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
38. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
[TBL] [Abstract][Full Text] [Related]
39. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
